Role of the charge, carbon chain length, and content of surfactant on the skin penetration of meloxicam-loaded liposomes

被引:86
作者
Duangjit, Sureewan [1 ]
Pamornpathomkul, Boonnada [1 ]
Opanasopit, Praneet [1 ]
Rojanarata, Theerasak [1 ]
Obata, Yasuko [2 ]
Takayama, Kozo [2 ]
Ngawhirunpat, Tanasait [1 ]
机构
[1] Silpakorn Univ, Fac Pharm, Sanamchandra Palace Campus,6 Ratchamankanai Rd, Muang 73000, Nakhon Pathom, Thailand
[2] Hoshi Univ, Dept Pharmaceut, Shinagawa Ku, Tokyo, Japan
来源
INTERNATIONAL JOURNAL OF NANOMEDICINE | 2014年 / 9卷
关键词
optimal liposome; optimization; transdermal drug delivery; surfactant charge; surfactant carbon chain length; surfactant content; PERCUTANEOUS-ABSORPTION; IN-VITRO; TRANSDERMAL DELIVERY; TOPICAL DELIVERY; FATTY-ACIDS; ENHANCEMENT; DRUG; OPTIMIZATION; CHOLESTEROL; CARRIERS;
D O I
10.2147/IJN.S60674
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
The objective of this study was to investigate the influence of surfactant charge, surfactant carbon chain length, and surfactant content on the physicochemical characteristics (ie, vesicle size, zeta potential, elasticity, and entrapment efficiency), morphology, stability, and in vitro skin permeability of meloxicam (MX)-loaded liposome. Moreover, the mechanism for the liposome-enhanced skin permeation of MX was determined by Fourier transform infrared spectroscopy and differential scanning calorimetry. The model formulation used in this study was obtained using a response surface method incorporating multivariate spline interpolation (RSM-S). Liposome formulations with varying surfactant charge (anionic, neutral, and cationic), surfactant carbon chain length (C4, C12, and C16), and surfactant content (10%, 20%, and 29%) were prepared. The formulation comprising 29% cationic surfactant with a C16 chain length was found to be the optimal liposome for the transdermal delivery of MX. The skin permeation flux of the optimal formulation was 2.69-fold higher than that of a conventional liposome formulation. Our study revealed that surfactants affected the physicochemical characteristics, stability, and skin permeability of MX-loaded liposomes. These findings provide important fundamental information for the development of liposomes as transdermal drug delivery systems.
引用
收藏
页码:2005 / 2017
页数:13
相关论文
共 38 条
  • [1] The role of lipid geometry in designing liposomes for the solubilisation of poorly water soluble drugs
    Ali, M. Habib
    Moghaddam, Behfar
    Kirby, Daniel J.
    Mohammed, Afzal R.
    Perrie, Yvonne
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 453 (01) : 225 - 232
  • [2] [Anonymous], PERCUTANEOUS PENETRA
  • [3] [Anonymous], 2003, TRANSDERMAL TOPICAL
  • [4] SURFACTANT EFFECTS IN PERCUTANEOUS-ABSORPTION .1. EFFECTS ON THE TRANSDERMAL FLUX OF METHYL NICOTINATE
    ASHTON, P
    WALTERS, KA
    BRAIN, KR
    HADGRAFT, J
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1992, 87 (1-3) : 261 - 264
  • [5] ENHANCEMENT OF NALOXONE PENETRATION THROUGH HUMAN-SKIN INVITRO USING FATTY-ACIDS, FATTY ALCOHOLS, SURFACTANTS, SULFOXIDES AND AMIDES
    AUNGST, BJ
    ROGERS, NJ
    SHEFTER, E
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1986, 33 (1-3) : 225 - 234
  • [6] SIDE-EFFECTS OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS ON THE SMALL AND LARGE-INTESTINE IN HUMANS
    BJARNASON, I
    HAYLLAR, J
    MACPHERSON, AJ
    RUSSELL, AS
    [J]. GASTROENTEROLOGY, 1993, 104 (06) : 1832 - 1847
  • [7] TRANSDERMAL DRUG CARRIERS - BASIC PROPERTIES, OPTIMIZATION AND TRANSFER EFFICIENCY IN THE CASE OF EPICUTANEOUSLY APPLIED PEPTIDES
    CEVC, G
    SCHATZLEIN, A
    BLUME, G
    [J]. JOURNAL OF CONTROLLED RELEASE, 1995, 36 (1-2) : 3 - 16
  • [8] Cevc G, 1995, HDB BIOL PHYSICS A, VI, P465
  • [9] Lipid tail chain asymmetry and the strength of membrane-induced interactions between membrane proteins
    Dan, Nily
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2007, 1768 (10): : 2393 - 2399
  • [10] Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease
    Degner, F
    Sigmund, R
    Zeidler, H
    [J]. CLINICAL THERAPEUTICS, 2000, 22 (04) : 400 - 410